Day: August 12, 2020

Positive data from the Sofpironium Bromide Phase 3 pivotal study in Japan presented in Q2 2020 by development partner, KakenBOULDER, Colo., Aug. 12, 2020 (GLOBE NEWSWIRE) — Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced financial results for the second quarter ended June 30, 2020 and provided a corporate update.“We announced several milestones during the first half of 2020 that strengthened our ability to execute our strategy to develop sofpironium bromide as a treatment for primary axillary hyperhidrosis in the U.S. and in Japan. Most notable are the successful completion of our U.S. Phase 3 long-term safety study, the positive...

NL-201 IND submission anticipated during fourth quarter of 2020Recent financing raises $71.4M in net proceeds to enable broad NL-201 clinical plan and product pipeline development into 2023Company to host Conference Call Today, August 12, 2020 at 1:30 p.m. Pacific / 4:30 p.m. EasternSEATTLE, Aug. 12, 2020 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the second quarter ending June 30, 2020 and a midyear corporate update.“All of the preclinical activities for NL-201 are substantially complete, and we are excited to be moving towards our first clinical trial in patients with advanced solid tumors,” said Jonathan Drachman, M.D., Chief Executive Officer...

BIRMINGHAM, Mich., Aug. 12, 2020 (GLOBE NEWSWIRE) — Conifer Holdings, Inc. (Nasdaq: CNFR) (“Conifer” or the “Company”) today announced results for the second quarter ended June 30, 2020.Second Quarter 2020 Financial Highlights (compared to the prior year period)Gross written premium increased 9.4% to $27.5 millionThe Company’s overall combined ratio was 100.5% (accident year combined ratio was 86.6%)Commercial lines represented approximately 93% of gross written premiumCommercial Lines combined ratio improved 6 percentage points to 101.7% (accident year combined ratio was 86.5%)Personal Lines combined ratio was 85.7% (accident year combined ratio was 86.9%)Net income of $1.5 million, or $0.16 per share, based on 9.6 million average shares outstandingBook value per share of $4.51 as of June 30, 2020, an improvement of 18.4% sequentially...

NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today reported financial results for its fiscal first quarter ended June 30, 2020.  Immunovant ended the quarter with approximately $280.3 million in cash.    Financial Highlights for Fiscal First Quarter ended June 30, 2020:R&D Expenses: Research and development expenses decreased by $1.6 million, from $18.5 million for the three months ended June 30, 2019, to $16.9 million for the three months ended June 30, 2020. Note that research and development expense for the three months ended June 30, 2019 included $10.0 million related to the achievement in May 2019 of the first development and regulatory milestone under Immunovant’s license agreement...

MITCHEL FIELD, N.Y., Aug. 12, 2020 (GLOBE NEWSWIRE) — Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM) today announced the award of a contract for precision oscillators for end use on US military platforms. The oscillators are a key component of the communication systems for a variety of platforms and follow several previous contracts for similar high performance oscillators. The contract value is $5.0M. The contract period of performance is approximately two years.FEI CEO Stan Sloane commented, “We are extremely pleased to receive this award and continue to supply these key components for US military applications. FEI’s precision oscillators continue to be selected for their excellent performance in dynamic environments, their high reliability and our track record of delivering on time.”About Frequency ElectronicsFrequency...

— Companies to jointly validate novel drug targets —— Scipher eligible for upfront, opt-in and milestone payments —— Galapagos to progress selected targets into drug discovery —Mechelen, Belgium and Boston, USA; 12 August 2020 – Galapagos NV (Euronext & Nasdaq: GLPG) and Scipher Medicine (Scipher), a Boston based privately held precision medicine company focused on autoimmune diseases, today announce a collaboration to advance novel drug targets identified by Scipher for the treatment of inflammatory bowel disease (IBD).   Scipher combines its proprietary Network Medicine Platform with molecular patient data and AI-based methods to identify novel targets and pathways in autoimmune diseases, including IBD.Scipher and Galapagos will jointly validate a suite of novel IBD targets discovered by...

— Ondernemingen valideren samen nieuwe targets voor medicijnontwikkeling–— Scipher ontvangt een vooruitbetaling en potentieel opt-in en mijlpaalbetalingen —— Ontwikkeling van geselecteerde targets naar medicijnontwikkeling door Galapagos —Mechelen, België en Boston, VS; 12 Augustus 2020 – Galapagos NV (Euronext & Nasdaq: GLPG) en Scipher Medicine (Scipher), een private onderneming uit Boston gefocust op precisiegeneeskunde en auto-immuunziekten, kondigen vandaag hun samenwerking aan om verder te werken op nieuwe medicijn targets, geïdentificeerd door Scipher, om potentiële behandelingen bij inflammatoire darmziekten te ontwikkelen.   Scipher combineert zijn Network Medicine platform met moleculaire data van patiënten en AI-gebaseerde methoden om nieuwe targets en pathways in auto-immuunziekten,...

WILMINGTON, Del., Aug. 12, 2020 (GLOBE NEWSWIRE) — Acorn Energy, Inc. (OTCQB: ACFN), a provider of Internet of Things (IoT) remote monitoring and control solutions for stand-by generators, gas pipelines, air compressors and other industrial equipment through its OmniMetrix subsidiary, today announced results for its second quarter (Q2’20) ended June 30, 2020. Acorn will host an investor call tomorrow, August 13th at 11:00 a.m. ET to discuss its results and outlook (details below).Jan Loeb, Acorn’s CEO, commented, “First, I want to thank the entire OmniMetrix team for their efforts and commitment amidst the challenges of the COVID-19 pandemic. As a provider of infrastructure support to critical industries, we’ve remained fully operational throughout the pandemic without any layoffs. In Q2, the company achieved 7% revenue growth...

RICHARDSON, Texas, Aug. 12, 2020 (GLOBE NEWSWIRE) — Fossil Group, Inc. (NASDAQ: FOSL) today announced financial results for the second quarter ended July 4, 2020.Second Quarter SummaryWorldwide net sales of $259 million decreased 48% on a reported basis and 47% in constant currency.  The year-over-year decline primarily reflects COVID-19 related impacts on a global basis, including retail and wholesale closures, throughout much of the quarter.On a constant currency basis, sales from the Company’s owned e-commerce websites increased 138% and third party marketplace e-commerce sales increased 20% compared to prior year.Gross margin of 54.3%, representing 140 basis points of expansion compared to the second quarter of 2019.The Company reduced operating expenses by $86 million, or 33%, on a year-over-year basis, due to both its...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2020(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)Market : NYSE Euronext ParisISIN Code: FR 0010417345* Total net = total number of voting rights attached to shares – shares without voting rightsAttachmentPDF Version